SIDE EFFECTS
The following adverse reactions have been observed in
women taking progestins:
Breakthrough bleeding.
Spotting.
Change in menstrual flow.
Amenorrhea.
Edema.
Changes in weight (decreases, increases).
Changes in cervical erosion and cervical secretions.
Cholestatic jaundice.
Rash (allergic) with and without pruritus.
Melasma or chloasma.
Mental depression.
Acne.
Breast enlargement/tenderness.
Headache/migraine.
Urticaria.
Abnormalities of liver tests (i.e., AST, ALT, Bilirubin).
Mood swings.
Nausea.
Insomnia.
Anaphylactic/anaphylactoid reactions.
Progestins may alter the result of pregnanediol determinations.
The following laboratory results may be altered by the
concomitant use of estrogens with progestins:
Hepatic function.
Coagulation tests increase in prothrombin, factors VII,
VIII, IX, and X.
Increase in PBI, BEI, and a decrease in T 3 uptake.
Reduced response to metyrapone test.
A statistically significant association has been demonstrated
between use of estrogen-progestogen combination drugs
and the following serious adverse reactions: thrombophlebitis,
pulmonary embolism, and cerebral thrombosis and embolism.
For this reason, patients on progestogen therapy should
be carefully observed. Although available evidence is
suggestive of an association, such a relationship has
been neither confirmed nor refuted for the following serious
adverse reactions:
Neuro-ocular lesions, e.g., retinal thrombosis and optic
neuritis.
The following adverse reactions have been observed in
patients receiving estrogen-progestogen combination drugs:
Rise in blood pressure in susceptible individuals.
Premenstrual-like syndrome.
Changes in libido.
Changes in appetite.
Cystitis-like syndrome.
Headache.
Nervousness.
Dizziness.
Fatigue.
Backache.
Hirsutism.
Loss of scalp hair.
Erythema multiforme.
Erythema nodosum.
Hemorrhagic eruption.
Itching.
In view of these observations, patients on progestogen
therapy should be carefully observed.
DRUG INTERACTIONS
No Information Provided.
| |
